Barclays initiated coverage on Orchestra BioMed with a new price target
$OBIO
Medicinal Chemicals and Botanical Products
Health Care
Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $12.00 | Buy | BTIG Research |
| 1/2/2025 | $16.00 | Overweight | Barclays |
| 8/22/2024 | $14.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $15.00 | Buy | B. Riley Securities |
| 1/19/2024 | $14.00 | Buy | Jefferies |
| 2/24/2023 | $15.00 | Overweight | Piper Sandler |
| 2/7/2023 | $20.00 | Buy | Chardan Capital Markets |